
National Health (COVID-19 Supply of Pharmaceutical Benefits) Amendment (Expansion of Telehealth and Telephone Attendances) Special Arrangement 2020
I, Adriana Platona, delegate of the Minister for Health, make the following special arrangement.
Adriana Platona
First Assistant Secretary
Technology Assessment and Access Division
Health Financing Group
Department of Health
Contents
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments
National Health (COVID-19 Supply of Pharmaceutical Benefits) Special Arrangement 2020
(1) This instrument is the National Health (COVID-19 Supply of Pharmaceutical Benefits) Amendment (Expansion of Telehealth and Telephone Attendances) Special Arrangement 2020.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | The day after this instrument is registered | 8 April 2020 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under section 100 of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
1 Section 5 (including note)
Repeal the section, substitute:
5 Simplified outline of this instrument
This instrument makes a special arrangement to make the supply of pharmaceutical benefits to patients who have been prescribed a pharmaceutical benefit as the result of a Medicare telehealth attendance or telephone attendance more convenient and effective. Medicare telehealth and telephone attendances have been introduced as a temporary measure in response to the impact of human coronavirus (COVID-19).
The instrument modifies arrangements for the supply of a pharmaceutical benefit on a paper-based prescription to enable certain supplies to be made based on an image of the prescription provided to the approved supplier by the PBS prescriber.
Note: Part VII of the Act, and regulations or other instruments made for the purposes of that Part, have effect subject to this instrument (see subsection 100(3) of the Act).
2 Subsection 6(1)
Insert:
approved hospital authority has the same meaning as in Part VII of the Act.
approved hospital authority dispenser means the pharmacist or practitioner by whom, or under whose supervision, a pharmaceutical benefit supplied by an approved hospital authority will be dispensed.
CTS claim has the same meaning as in Part VII of the Act.
3 Subsection 6(1) (definition of patient at risk of COVID-19 virus)
Repeal the definition.
4 Subsection 6(1) (definition of phone attendance)
Repeal the definition, substitute:
phone attendance has the same meaning as in section 6 of the Health Insurance (Section 3C General Medical Services – COVID-19 Telehealth and Telephone Attendances) Determination 2020.
Poisons Standard means the current Poisons Standard (within the meaning of the Therapeutic Goods Act 1989).
5 Subsection 6(1) (definition of telehealth attendance)
Repeal the definition, substitute:
telehealth attendance has the same meaning as in section 6 of the Health Insurance (Section 3C General Medical Services – COVID-19 Telehealth and Telephone Attendances) Determination 2020.
6 Subsection 6(2)
Repeal the subsection, substitute:
7 Subsection 7(1)
Repeal the subsection, substitute:
(1) Division 2 of this Special Arrangement applies to all pharmaceutical benefits available for supply under Part VII of the Act other than a pharmaceutical benefit:
(a) referred to in Schedule 8 to the Poisons Standard, or referred to in both Schedule 4 and Appendix D to the Poisons Standard; and
(b) which may not be supplied on the basis of a digital image of a prescription or a copy of prescription under a law in force in the State or Territory in which the pharmaceutical benefit would be supplied.
8 Section 9
Repeal the section, substitute:
9 Supplies to which the Special Arrangement applies
Note: Subsection 3C(1) enables the Minister to determine that, for the purposes of the Health Insurance Act 1973, the National Health Act 1953 and associated legislation, a health service not already specified in the general medical services table is to be treated as a professional or medical service and that the health service should be treated as if there were an item in that table.
9 Section 10
Repeal the section, substitute:
10 Modified application of section 44 of the Regulations - supplies on first presentation of prescription
Note: a paper-based prescription for a pharmaceutical benefit will commonly include a part of the prescription that is the pharmacist/patient copy and a part of the prescription that is the Medicare/DVA copy - see subsection 40(2) of the Regulations.
10 Section 11
Repeal the section, substitute:
11 Modified application of section 51 of the Regulations - repeated supplies of pharmaceutical benefits
the supplier of the benefit meets the requirements of paragraph 51(4)(b) or 51(4)(c) of the Regulations, as appropriate, if the supplier writes the words “immediate supply necessary” and signs the copy of the prescription, the digital image of the prescription or a print out of the digital image of the prescription.
12 Modified application of section 52 of the Regulations - repeat authorisations
and subsequent supplies of the pharmaceutical benefit can be made under the prescription at the time of supply.
Requirement to prepare repeat authorisation
13 Modified application of section 53 of the Regulations - deferred supply
14 Keeping documents - approved suppliers
An approved supplier must keep a document referred to in an item in the following table for a period of 2 years from the date of supply if:
(a) the supply was made on the basis of:
(b) the supply is of a kind referred to in that item.
Documents to be kept | ||
Item | Kind of supply | Document |
1 | Both of the following apply in relation to the supply: (a) the supply was the first or only supply of a pharmaceutical benefit authorised by the prescription; (b) a CTS claim is made for the supply. | The digital image, print out of the digital image or the copy of the prescription. |
2 | Both of the following apply in relation to the supply: (a) the supply was on the basis of a repeat authorisation or a deferred supply authorisation; (b) a CTS claim is made for the supply. | The repeat authorisation or deferred supply authorisation. |
3 | After the supply, there are no remaining supplies of pharmaceutical benefits that are authorised by the prescription. | The digital image, print out of the digital image or the copy of the prescription. |
15 Keeping documents - PBS prescribers
Where a PBS prescriber has written a prescription referred to in subsection 10(1) and the PBS prescriber has given an approved medical practitioner, approved pharmacist or approved hospital authority dispenser a digital image or copy of the prescription, the PBS prescriber must keep the prescription for a period of at least 2 years from the date the prescription.
11 Section 12
Renumber as section 16.
12 At the end of the instrument
Add:
13 Continued application of Special Arrangement as in force before commencement of the National Health (COVID-19 Supply of Pharmaceutical Benefits) Amendment (Expansion of Telehealth and Telephone Attendances) Special Arrangement 2020